Evidence map›Paper›PMID 38873095›Full record

ReviewFrontiers in cellular and infection microbiology2024

A rare case of successful treatment of peritoneal dialysis patient with

Ruizhi Xie, Ying Ling, Yaru Huang, Lulu Qin, Kun Bao, Xindong Qin

Abstract readCase ReportsReview
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Spread of carbapenemase-producingEmerging microbes & infections · 2026
    Article
  2. IDCases · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ruizhi Xie *The Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Ying Ling *The Sixth Clinical Medical College, Shenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China.
Yaru HuangThe College of Basic Medical Sciences of Guangzhou University of Chinese Medicine, Guangzhou, China.
Lulu QinThe Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Kun BaoThe Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Xindong QinThe Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serratia marcescens, as a Gram-negative opportunistic pathogen, is a rare cause of peritonitis and has worse clinical outcomes than Gram-positive peritonitis. In this case report, we describe a case of Serratia marcescens associated peritonitis that was successfully cured without catheter removal. A 40-year-old male patient with peritoneal dialysis who worked in the catering industry was admitted to the hospital for 16 hours after the discovery of cloudy peritoneal dialysate and abdominal pain. Ceftazidime and cefazolin sodium were immediately given intravenously as an empirical antibiotic regimen. After detecting Serratia marcescens in the peritoneal diasate culture, the treatment was switched to ceftazidime and levofloxacin. The routine examination of peritoneal dialysate showed a significant decrease in white blood cells, the peritoneal dialysate became clear, and the peritoneal dialysis catheter was retained. The patient was treated for 2 weeks and treated with oral antibiotics for 1 week. It is necessary to further strengthen the hygiene of work environment to prevent Serratia marcescens infection in peritoneal dialysis patients. We recommend that patients with Serratia marcescens associated peritonitis should be treated with a combination of antibiotics as early as possible empirically, and at the same time, the peritoneal dialysis fluid culture should be improved, and the antibiotic regimen should be timely adjusted according to the drug sensitivity results. For patients with clinical symptoms for more than 3 days, considering the strong virulence of Serratia marcescens, whether to use meropenem directly or not can provide a reference for clinical decision-making. Further clinical studies are needed to achieve more precise anti-infective treatment.

Indexed as

Anti-Bacterial AgentsPeritoneal DialysisPeritonitisSerratia InfectionsSerratia marcescensAdultCefazolinCeftazidimeDevice RemovalHumansLevofloxacinMaleTreatment OutcomeAnti-Bacterial AgentsCefazolinCeftazidimeLevofloxacincase reportinfection routeperitoneal dialysisperitonitisSerratia marcescenstreatment

Identifiers

PMID38873095
PMCPMC11169698

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.